The Lilly train keeps on rolling thanks to Mounjaro and Zepbound. And there's more growth to be had.
We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Source: CNBC
Original reporting
CNBC: read the full reportRelated stories
CNBC
Alaska Gov. orders probe of Peltola Senate campaign's alleged recruitment of 2nd Sullivan
Alaska's election could determine which party has a majority in the Senate. GOP Sen. Dan Sullivan faces a strong challenge from Democrat Mary Peltola.
CNBC
Big Oil earnings are set to surge. Why investors may want to be cautious
Big Oil earnings are coming. Why guidance could matter most and why the the charts suggest investors should be cautious.
CNBC
Third-quarter U.S. GDP increases a better-than-expected 3.4% as September inflation accelerates
The personal consumption expenditures price index was projected to increase 0.5% in September for an annual rate of 3.7%, according to the Dow Jones consensus.
CNBC
Cruise companies aim to keep fuel costs down. Their strategies for doing so differ
Carnival is cutting fuel use, while Royal Caribbean and Norwegian rely on "hedging" to keep fuel costs down amid conflict in the Middle East.
CNBC
Some investors have midterm election jitters. Here’s what history shows about stocks
Investors are anxious about the 2026 midterms. Here's what historical S&P 500 data shows happened before and after past elections.
CNBC
Aon CEO warns AI data center insurance risks could threaten financing
Aon CEO Greg Case said concentration risk at AI data centers could constrain insurance capacity and alter financing for new projects.